http://www.acc.org/Feed?clinicalTopicID=3bf13d0e-30db-413f-b1ef-03f397769a1a Clinical Topic Feed: Valvular Heart Disease en /Latest-in-Cardiology/Articles/2026/09/02/12/37/eagles-eye-view-02sep2026 In this week’s View, Dr. Eagle evaluates how sacubitril/valsartan promotes cardiac remodeling, but not functional capacity, in nonobstructive hypertrophic cardiomyopathy. 1788357600000 Articles and Stories /Education-and-Meetings/Patient-Case-Quizzes/2026/09/01/17/37/Right-Heart-Wrong-Way A full-term male infant develops respiratory distress shortly after birth. An echocardiogram shows Ebstein anomaly with severe tricuspid valve (TV) displacement and severe regurgitation, estimated right ventricular systolic pressure (RVSP) 35 mm Hg above the right atrial (RA) pressure... 1788305220000 Educational Activities /Latest-in-Cardiology/Articles/2022/01/01/01/01/ACC-Featured-Jobs Ready to explore a new professional opportunity? Browse the list below of featured jobs and take the next step in your career! 1788305160000 Articles and Stories /Latest-in-Cardiology/Articles/2026/09/01/01/JACC-in-a-Flash Featured topics and Editors' Picks from all of ACC's JACC Journals. 1788264600000 Articles and Stories /Latest-in-Cardiology/Articles/2026/09/01/01/Journal-Wrap The hottest research from various peer-reviewed journals – handpicked weekly by the ACC. 1788264540000 Articles and Stories /Latest-in-Cardiology/Articles/2026/08/29/08/48/sun-545am-combo-tavi-esc-2026 Three late-breaking trials presented at ESC Congress 2026 offer new insights into the management of structural heart disease and heart failure (HF), spanning coronary revascularization during TAVI, transcatheter treatment of tricuspid regurgitation, and post-TAVI antithrombotic therapy. Together, the TAVI PCI, ACASA-TAVI and TRIC-I-HF studies provide important evidence to help refine treatment strategies and improve patient outcomes. 1788091440000 Articles and Stories /Latest-in-Cardiology/Articles/2026/08/24/12/30/sat-jacc-journals-esc-2026 Several abstracts and e-posters presented at ESC Congress 2026 and simultaneously published across the JACC family of journals highlight the expanding role of precision medicine, novel therapeutics, and advanced risk stratification across cardiovascular care. 1788002340000 Articles and Stories /Latest-in-Cardiology/Articles/2026/08/24/12/30/fri-reboot-paradox-esc-2026 Despite premature termination limiting the precision of mortality estimates, the REBOOT-PARADOX trial offers rare randomized, long-term patient-level data examining whether TAVR adds a survival benefit compared with optimal medical therapy (OMT) in symptomatic patients with paradoxical low-flow, low-gradient aortic stenosis (pLFLG). 1787928180000 Articles and Stories /Latest-in-Cardiology/Articles/2023/05/30/10/47/Clinical-Practice-Algorithm-For-the-Follow-Up-of-Unrepaired-and-Repaired-Ventricular-Septal-Defects Ventricular septal defects (VSDs) are the most common form of congenital heart disease (CHD) diagnosed in childhood. There is a wide variation in clinical practice for the management of common types of VSDs. 1787745480000 Articles and Stories /Latest-in-Cardiology/Articles/2022/03/08/19/34/Clinical-Practice-Algorithm-For-the-Follow-up-of-Unrepaired-and-Repaired-SASD There is lack of evidence-based guidelines to help cardiologists determine the frequency of follow-up and testing in children with congenital heart disease (CHD). Thus, there remains a wide variation in clinical practice even for the management of common types of CHD. 1787745120000 Articles and Stories